Review
Open access
Aug 2026
Ensuring access to Tau-Targeting therapies for MAPT frontotemporal dementia: patient community priorities for regulators and industry
This document outlines seven key requests that Cure MAPT FTD made on May 23, 2025 in a Patient Listening Session to the U.S. Food and Drug Administration regarding clinical trial design and the approval of tau-targeting therapies for MAPT FTD patients.
Linde L. Jacobs, T. Steel, Barbara Dawson et al.
· npj Dementia · 0 citations